Karo Pharma gains full control of Teva OTC portfolio

8 February 2021 - Deborah Wilkes

Premium

Sweden’s Karo Pharma is acquiring a portfolio of OTC brands – including the Flux fluoride rinse and Decubal skincare products – from Israel’s Teva for EUR84 million (USD102 million).

Click tags below for more information on topics:

Karo Pharma Teva

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: